Pfizer Inc.: Pfizer's Abrocitinib Receives Positive CHMP Opi

CHMP also recommends XELJANZ (tofacitinib) approval for the treatment of adults with active ankylosing spondylitis Pfizer Inc. (NYSE: PFE) today announced that the European Medicines Agency's

Related Keywords

Germany , United States , Norway , Iceland , Japan , Paris , France General , France , Lauziere , Rhôalpes , United Kingdom , Liechtenstein , Japanese , Diamant Thaci , Michael Corbo , Postep Derm Alergol , Pharmacovigilance Risk Assessment Committee , Linkedin , University Of Luebeck , Pfizer , Pfizer Inc , European Union , University Of Maryland Medical Center , Committee For Medicinal Products Human Use , Drug Administration , European Commission , Pfizer Global Product Development , Regulatory Agency , Exchange Commission , Youtube , Japanese Ministry Of Health , European Medicines Agency , Medicinal Products , Human Use , Chief Development Officer , Inflammation Immunology , Pfizer Global Product , Comprehensive Center , Inflammation Medicine , United Kingdom Medicines , Japanese Ministry , Medicine Products , Drug Safety Communication , Atopic Dermatitis , Ankylosing Spondylitis , Barr Virus Associated , Nonsteroidal Anti Inflammatory Drugs , Enzyme Elevations , Important Safety Information , Prescribing Information , Breakthroughs That Change Patient Lives , Pfizer News , Annual Report , Looking Information , Factors That May Affect Future , Accessed September , Maryland Medical , Abrocitinib , Eceives , Positive , Thmp , Opinion , Treatment , Adults , Moderate , Evere , Topic , Dermatitis ,